Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer

Annals of Oncology

Volumn 14, Issue 10, 2003, Pages 1501-1504

  Sehouli, J ^a   Mustea, A ^a   Koensgen, D ^a   Chen, F C K ^a   Lichtenegger, W ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Interleukin 1 receptor antagonist; Ovarian cancer; Polymorphism

Indexed keywords

DNA FRAGMENT; GENOMIC DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGE; AGED; ALLELE; ARTICLE; ASCITES; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EPITHELIUM TUMOR; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-1; RISK FACTORS;

EID: 0142247628     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg413     Document Type: Article

References (40)

1. Landis SH, Murray T, Bolden S. Cancer statistic. CA-Cancer J Clin 1999; 8: 49-54.
2. Chang J, Bridgewater J, Gore M et al. Non-surgical aspects of ovarian cancer. Lancet 1994; 343: 335-341.
3. Dhar K, Branigan K, Howells R et al. Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer 1999;9:342-347.
4. Lichtenegger W, Sehouli J, Buchmann E et al. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 1998; 24: 447-451.
5. Schrecengost A. Ovarian mass - benign or malignant? AORN J 2002; 76: 792-802.
6. Jeremias J, Ledger WJ, Witkin S. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. Am J Obstet Gynecol 2000; 182: 283-285.
7. Strauss JF. Unravelling the genetics of complex disorders of reproduction. In Countinuto EM, Spinola P (eds): Reproductive Medicine: a Millennium Review. New York, NY: Parthenon Publishing Group 1999; 284-287.
8. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002; 34: 204-209.
9. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
10. Iizuka N, Hazama S, Hirose K. Interleukin 1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 1999; 142: 179-184.
11. Eisenberg SP, Brewer MT, Verderber E et al. Interleukin-1 receptor antagonist is a member of the interleukin 1 gene family. Evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1991; 88: 5232-5236.
12. Dinarello C. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16: 457-499.
13. Arend WP. Interleukin 1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 1990; 2: 193-205.
14. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-310.
15. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur J Immunol 1998; 28: 2598-2602.
16. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47: 195-198.
17. Pociot F, Molvig J, Wogensen L et al. A TaqI polymorphism in the human interleukin-1 β (IL-1β) gene correlates with IL-1β secretion in vivo. Eur J Clin Invest 1992; 22: 396-402.
18. Licastro F, Pedrine S, Ferri C et al. Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 2000; 48: 388-391.
19. Hulkkonen J, Laippala P, Hurne M. A rare allele combination of interleukin gene complex is associated with high interleukin-1β plasma levels in healthy individuals. Eur Cytokine Netw 2000; 11: 251-255.
20. Apte R, Voronov E. Interleukin - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12: 277-290.
21. Marth C, Zeimet AG, Herold M et al. Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 1996; 67: 826-830.
22. Chen Z, Fadiel A, Feng Y et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1α and epidermal growth factor. Cancer 2001; 92: 3068-3075.
23. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
24. Sehouli J, Mustea A. Interleukin-1 receptor antagonist gene polymorphism and cancer. Clin Infect Dis 2002; 34: 1535-1536.
25. Sehouli J, Mustea A, Konsgen D et al. Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Res 2002; 22: 3421-3424.
26. Barber MD, Powell JJ, Lynch SF et al. A polymorphism of the interleukin-1β gene influences survival in pancreatic cancer. Br J Cancer 2000; 83: 1443-1447.
27. Sehouli J, Lichtenegger W, Hauptmann S, Dietel M. Therapie von Borderline-Tumoren des Ovars. Frauenarzt 2002; 43: 1202-1207.
28. Tarlow JK, Blakemore AIF, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
29. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-245.
30. Corbacioglu S, Pietsch T, Koenig A, Welte K. Interleukin-1 receptor antagonist: a powerful inhibitor of tumor vascularization and tumor growth in vivo. In VI International Symposium on Pediatric Neuro-Oncology, MD Anderson Cancer Center, Houston, TX 1994; 35 (Abstr).
31. Arend WP. Interleukin-1 receptor antagonist. A new member of the interleukin family. J Clin Invest 1991; 88: 1445-1451.
32. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-1325.
33. Vamvakopoulos J, Green C, Metcalfe S. Genetic control of IL-1β bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 2002; 32: 2988-2996.
34. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55.
35. Unfried G, Tempfer C, Schneeberger C et al. Interleukin 1 receptor antagonist polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril 2001; 75: 683-687.
36. Machado JC, Pharoah P, Sousa S et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121: 823-829.
37. Mustea A, Sehouli J, Sofroni D et al. Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res 2002; 1B: 486 (Abstr).
38. Hefler L, Ludwig E, Lebrecht A et al. Polymorphism of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Invest 2002; 9: 386-390.
39. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 2001; 61: 908-911.
40. Gershoni-Baruch R, Dagan E, Israeli D et al. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 2000; 36: 2313-2316.